1. Miller PW, Long NJ, Vilar R, et al. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008;47:8998–9033.
2. Choi JY, Kim CH, Jeon TJ, et al. Evaluation of dopamine transporters and D2 receptors in hemiparkinsonian rat brains in vivo using consecutive PET scans of [18F]FPCIT and [18F]fallypride. Appl Radiat Isot. 2012;70:2689–94.
3. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971;367:69–93.
4. Maeda J, Ji B, Irie T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci. 2007;27:10957–68.
5. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537:50–6.
6. Harada A, Suzuki K, Kamiguchi N, et al. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PLoS One. 2015;10:e0122197.
7. Tomimatsu Y, Cash D, Suzuki M, et al: TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge. Neuroscience. 2016;339:180–90.
8. Takano A, Stenkrona P, Stepanov V, et al: A human [11C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor. Neuroimage. 2016;141:10–7.
9. Macek TA, McCue M, Dong X, et al: A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res. 2019;204:289–94.
10. Bender AT, Beavo JA: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488–520.
11. Keravis T, Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol. 2012;165:1288–305.
12. Naganawa M, Waterhouse RN, Nabulsi N, et al. First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430. J Nucl Med. 2016;57(9):1388–95.
13. DaSilva JN, Lourenco CM, Meyer JH, et al. Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imaging. 2002;29:1680–3.
14. Boscutti G, A Rabiner E, Plisson C. PET Radioligands for imaging of the PDE10A in human: current status. Neurosci Lett. 2019;691:11–7.
15. Castro A, Jerez MJ, Gil C, et al. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev. 2005;25:229–44.
16. Kishimoto M, Komine M, Hioki T, et al. Real-world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018;45:1345–8.
17. Safavi M, Baeeri M, Abdollahi M. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Drug Discov. 2013;8:733–51.
18. Lakics V, Karran EH, Boess FG: Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010;59:367–374.
19. Miro X, Perez-Torres S, Palacios JM, et al: Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse. 2001;40:201–14.
20. Reyes-Irisarri E, Perez-Torres S, Mengod G: Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience. 2005;132:1173–85.
21. Kelly MP, Adamowicz W, Bove S, et al: Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain. Cell Signal. 2014;26:383–97
22. Morales-Garcia JA, Redondo M, Alonso-Gil S, et al: Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS One. 2011;6:e17240.
23. Morales-Garcia JA, Alonso-Gil S, Gil C, et al: Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats. Stem Cells Transl Med. 2015;4:564– 75.
24. Bartolome F, de la Cueva M, Pascual C, et al: Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimers Res Ther. 2018;10:24.
25. Perez-Gonzalez R, Pascual C, Antequera D, et al: Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34:2133–45.
26. Ciccocioppo R, Li H, de Guglielmo G, et al: Phosphodiesterase type 7: a novel target for smoking cessation -preclinical evidence-. Alcohol Alcohol. 2014;49(S1):i34.
27. Martín-Álvarez R, Paúl-Fernández N, Palomo V, et al: A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. J Chem Neuroanat. 2017;80:27–36.
28. Redondo M, Zarruk JG, Ceballos P, et al: Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem. 2012;47:175–85.
29. McQuown S, Paes D, Baumgärtel K, et al. Pharmacological inhibition of phosphodiesterase 7 enhances consolidation processes of spatial memory. Neurobiol Learn Mem. 2021;177:107357.
30. Thomae D, Servaes S, Vazquez N, et al: Synthesis and preclinical evaluation of an 18F labeled PDE7 inhibitor for PET neuroimaging. Nucl Med Biol. 2015;42:975–81.
31. Thomae D, Servaes S, Vazquez N, et al: Synthesis and preclinical evaluation of two novel radioligands for PDE7 imaging in the brain. The 21st International Symposium on Radiopharmaceutical Sciences (ISRS 2015), University of Missouri, Columbia, Missouri, USA, May 26–31, 2015. J Labelled Comp Radiopharm. 2015;58:S295.
32. Chen J, Gu G, Chen M, et al: Rapid identification of a novel phosphodiesterase 7B tracer for receptor occupancy studies using LC-MS/MS. Neurochem Int. 2020;137:104735.
33. Gil C, Campillo NE, Perez DI, et al: PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Ther Pat. 2008;18:1127–39.
34. Mitsubishi Tanabe Pharma Corporation: Bicyclic Nitrogenated Heterocyclic Compound. Patent pending: WO 2018/038265, PCT/JP2017/030609
35. Koizumi Y, Tanaka Y, Matsumura T, et al: Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety. Bioorg Med Chem. 2019;27:3440–50.
36. Oi N, Suzuki M, Terauchi T, et al: Synthesis and evaluation of novel radioligands for positron emission tomography imaging of the orexin-2 receptor. J Med Chem. 2013;56:6371–85.
37. Iwata R, Ido T, Takahashi T, et al: Optimization of [11C]HCN production and no-carrier- added [1-11C]amino acid synthesis. Int J Rad Appl Instrum A. 1987;38:97–102.
38. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.
39. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–7.
40. Ichise M, Liow JS, Lu JQ, et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096–112.
41. Akaike H, A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19:716–23.
42. Patel S, Gibson R: In vivo site-directed radiotracers: a mini-review. Nucl Med Biol. 2008;35:805–15.
43. Kubota M, Seki C, Kimura Y, et al: A first-in-human study of 11C-MTP38, a novel PET ligand for phosphodiesterase 7. Eur J Nucl Med Mol Imaging. 2021 Feb 10. doi: 10.1007/s00259-021-05235-0. Epub ahead of print.
44. Morales-Garcia JA, Echeverry-Alzate V, Alonso-Gil S, et al: Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. Stem Cells. 2017;35:458–72.
45. Gunn RN, Rabiner EA: Imaging in central nervous system drug discovery. Semin Nucl Med. 2017;47:89–98.
46. Rabiner EA, Beaver J, Makwana A, et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry. 2011;16:826–35.
47. Lindner JR, Link J. Molecular Imaging in Drug Discovery and Development. Circ Cardiovasc Imaging. 2018;11:e005355.
48. Matthews PM, Rabiner EA, Passchier J, et al. Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol. 2012;73:175–86.